Specialist consultation for initiation Medical oncologist Outpatient 53% (BRAF $145.20 TBD of dacarbazine ( or fotemustine) negative patients) $72.65 as first-line chemotherapy, with or without a T cell immunostimulant (ipilimumab) or fotemustine as a second line treatment and regular follow-up MBS 110 MBS 116 Dacarbazine (first line treatment) Medical oncologist Day patient TBD (BRAF TBD negative patients) Fotemustine (first or second line Medical oncologist Day patient TBD (BRAF $1206.86/vial TBD treatment) negative patients) Ipilimumab (second line treatment) Medical oncologist Day patient TBD (BRAF TBD negative patients) Drug administration for < 1 hr Medical oncologist Day patient 53% (BRAF TBD infusion (MBS 13915) negative patients) Public hospital outpatient Medical oncologist Day patient 53% (BRAF TBD admission for drug administration negative patients) Resources provided in association with proposed intervention – to manage adverse events from dabrafenib Cutaneous squamous cell Medical oncologist Outpatient 12%b TBD TBD carcinoma monitoring Cutaneous squamous cell Dermatologist Outpatient 12%b TBD TBD carcinoma excision MBS 31280 $149.95 MBS 31285 $201.90 MBS 31290 $236.55 Monitoring for QT prolongation, 12 Medical oncologist Outpatient 47%a TBD $30.05 TBD lead electrocardiography (MBS 11700) Resources provided to deliver drug therapy - current scenario
Specialist consultation for initiation of dacarbazine ( or fotemustine) as first-line chemotherapy, with or without a T cell immunostimulant (ipilimumab) or fotemustine as a second line treatment and regular follow-up MBS 110 MBS 116 Medical oncologist Outpatient 53% (BRAF negative patients) $145.20 $72.65 TBD Dacarbazine (first line treatment) Medical oncologist Day patient TBD (BRAF negative patients) TBD Fotemustine (first or second line treatment) Medical oncologist Day patient TBD (BRAF negative patients) $1206.86/vial TBD Ipilimumab (second line treatment) Medical oncologist Day patient TBD (BRAF negative patients) TBD Drug administration for < 1 hr infusion (MBS 13915) Medical oncologist Day patient 53% (BRAF negative patients) TBD Public hospital outpatient admission for drug administration Medical oncologist Day patient 53% (BRAF negative patients) TBD Resources provided in association with proposed intervention – to manage adverse events from dabrafenib Cutaneous squamous cell carcinoma monitoring Medical oncologist Outpatient 12%b TBD TBD Cutaneous squamous cell carcinoma excision MBS 31280 MBS 31285 MBS 31290 Dermatologist Outpatient 12%b TBD $149.95 $201.90 $236.55 TBD Monitoring for QT prolongation, 12 lead electrocardiography (MBS 11700) Medical oncologist Outpatient 47%a TBD $30.05 TBD Resources provided to deliver drug therapy - current scenario
1207-Final-DAP-accessible.docx